RT Journal Article
SR Electronic
T1 A Universal Day Zero Infectious Disease Testing Strategy Leveraging CRISPR-based Sample Depletion and Metagenomic Sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.12.22274799
DO 10.1101/2022.05.12.22274799
A1 Chan, Agnes P.
A1 Siddique, Azeem
A1 Desplat, Yvain
A1 Choi, Yongwook
A1 Ranganathan, Sridhar
A1 Choudhary, Kumari Sonal
A1 Diaz, Josh
A1 Bezney, Jon
A1 DeAscanis, Dante
A1 George, Zenas
A1 Wong, Shukmei
A1 Selleck, William
A1 Bowers, Jolene
A1 Zismann, Victoria
A1 Reining, Lauren
A1 Highlander, Sarah
A1 Hakak, Yaron
A1 Brown, Keith
A1 Armstrong, Jon R.
A1 Schork, Nicholas J.
YR 2022
UL http://medrxiv.org/content/early/2022/05/16/2022.05.12.22274799.abstract
AB The lack of preparedness for detecting the highly infectious SARS-CoV-2 pathogen, the pathogen responsible for the COVID-19 disease, has caused enormous harm to public health and the economy. It took ∼60 days for the first reverse transcription quantitative polymerase chain reaction (RT-qPCR) tests for SARS-CoV-2 infection developed by the United States Centers for Disease Control (CDC) to be made publicly available. It then took >270 days to deploy 800,000 of these tests at a time when the estimated actual testing needs required over 6 million tests per day. Testing was therefore limited to individuals with symptoms or in close contact with confirmed positive cases. Testing strategies deployed on a population scale at ‘Day Zero’ i.e., at the time of the first reported case, would be of significant value. Next Generation Sequencing (NGS) has such Day Zero capabilities with the potential for broad and large-scale testing. However, it has limited detection sensitivity for low copy numbers of pathogens which may be present. Here we demonstrate that by using CRISPR-Cas9 to remove abundant sequences that do not contribute to pathogen detection, NGS detection sensitivity of COVID-19 is comparable to RT-qPCR. In addition, we show that this assay can be used for variant strain typing, co-infection detection, and individual human host response assessment, all in a single workflow using existing open-source analysis pipelines. This NGS workflow is pathogen agnostic, and therefore has the potential to transform how both large-scale pandemic response and focused clinical infectious disease testing are pursued in the future.SIGNIFICANCE STATEMENT The lack of preparedness for detecting infectious pathogens has had a devastating effect on the global economy and society. Thus, a ‘Day Zero’ testing strategy, that can be deployed at the first reported case and expanded to population scale, is required. Next generation sequencing enables Day Zero capabilities but is inadequate for detecting low levels of pathogen due to abundant sequences of little biological interest. By applying the CRISPR-Cas system to remove these sequences in vitro, we show sensitivity of pathogen detection equivalent to RT-qPCR. The workflow is pathogen agnostic, and enables detection of strain types, co-infections and human host response with a single workflow and open-source analysis tools. These results highlight the potential to transform future large-scale pandemic response.Competing Interest StatementA.S., Y.D., S.R., K.S.C., J.D., J.B., D.D., Z.G., Y.H., J.R.A., K.B., Y.H., and N.J.S. have stock in Jumpcode Genomics, Inc. N.J.S provides paid consulting services to Jumpcode Genomics, Inc. Y.H. is a member of the board of Jumpcode Genomics, Inc.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Translational Genomics Research Institute IRBI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors